13998 Federal Register / Vol. 60, No. 50 / Wednesday, March 15, 1995 / Notices

and grocery items in supermarkets, or

narrower product markets contained

therein, in the ‘‘New Orleans metro

area,’’ which consists of the parishes of

Orleans, Jefferson, and St. Bernard, or

narrower geographic markets contained

therein. According to the draft

complaints, the relevant markets are

highly concentrated and entry is

difficult or unlikely. Schwegmann’s

acquisition of National may reduce

competition in these markets by

eliminating the direct competition

between Schwegmann and National, by

increasing the likelihood that

Schwegmann will become a dominant

firm, and by increasing the likelihood of

collusive behavior among the remaining

competitors.

The agreement containing consent

order attempts to remedy the

Commission’s competitive concerns

about the acquisition. Under the terms

of the proposed order, Schwegmann

must divest seven supermarkets within

twelve months, to a purchaser approved

by the Commission. If Schwegmann

fails to satisfy the divestiture provisions,

the Commission may appoint a trustee

to divest supermarkets to satisfy the

terms of the order. The seven

supermarkets to be divested are:

1. That Stanley supermarket located at

315 E. Judge Perez Drive (store No.

79), Chalmette, LA;

2. Canal Villere supermarket located at

4726 Paris Avenue (store No. 24),

New Orleans, LA;

3. Canal Villere supermarket located at

2125 Caton Street (store No. 25), New

Orleans, LA;

4. That Stanley supermarket located at

4223 Chef Menteur Highway (store

No. 8), New Orleans, LA;

5. That Stanley supermarket located at

9319 Jefferson Highway (store No. 33),

River Ridge, LA;

6. Canal Villere supermarket located at

5245 Veterans Memorial Boulevard

(store No. 93), Metairie, LA;

7. Canal Villere supermarket located at

135 Robert E. Lee Boulevard (store

No. 83), New Orleans, LA.

For a period of ten years from the date

the order becomes final, the order also

prohibits Schwegmann from acquiring,

without prior Commission approval,

supermarket assets located in, or any

interest (such as stock) in any entity that

owns or operates a supermarket located

in, the New Orleans metro area. This

does not prevent Schwegmann from

constructing new supermarket facilities

on its own; nor does it prevent

Schwegmann from leasing facilities not

operated as supermarkets within the

previous six months.

For a period of ten years, if

Schwegmann sells or leases a

supermarket to another person,

Schwegmann may not enter into or

enforce any agreement that would

restrict the ability of that person to

operate a supermarket. In addition,

subject to certain exceptions,

Schwegmann may not remove any

equipment from a supermarket it owns

or operates prior to a sale, sublease,

assignment, or change in occupancy.

The respondent is required to provide

to the Commission a report of

compliance with the order within sixty

(60) days following the date the order

becomes final, every sixty (60) days

thereafter until the divestitures are

completed, and annually for a period of

ten years.

The purpose of this analysis is to

invite public comment on the proposed

consent order to aid the Commission in

its determination of whether it should

make final the proposed consent order

contained in the agreement.

This analysis is not intended to

constitute an official interpretation of

the agreement and proposed consent

order, nor is it intended to modify the

terms of the agreement and proposed

consent order in any way.

Donald S. Clark,

Secretary.

Concurring Statement of Commissioner

Mary L. Azcuenaga

Re: Schnuck Markets, Inc., File No. 941–

0131; Schwegmann Giant Super

Markets, Inc., File No. 941–0130

The two complaints allege geographic

markets comprising ‘‘the St. Louis MSA,

and narrower markets contained

therein’’ and ‘‘metro New Orleans,

Louisiana area, which consists of the

parishes of Orleans, Jefferson, and St.

Bernard, and marrower markets

contained therein.’’ Although I question

the broad geographic markets alleged,

the investigational record contains

sufficient information to support a

finding of reason to believe with respect

to small, discrete geographic markets

located within the broad regions alleged

in the complaint, and the stores to be

divested were selected with a view to

remedying competitive concerns in the

small, discrete markets.

In addition, the complaints allege as

the product market ‘‘the retail sale of

food and grocery products in

supermarkets, and narrower markets

contained therein.’’ A serious argument

can be made that the market should

include sales of food and groceries in

certain stores other than traditional

supermarkets. Since the investigational

record suggests that the concentration is

high even if additional sales are

included in the market, the issue need

not be resolved at this time.

Accordingly, I concur in the decision to

accept the consent agreements for

publication.

[FR Doc. 95–6343 Filed 3–14–95; 8:45 am]

BILLING CODE 6750–01–M

GENERAL SERVICES

ADMINISTRATION

Construction of FDA Regional Office

and Laboratory; Environmental Impact

Statement; Jamaica, Queens County,

New York

AGENCY: General Services

Administration (GSA).

ACTION: Notice of Intent to hold a public

scoping meeting and prepare and file an

Environmental Impact Statement (EIS).

SUMMARY: The GSA is issuing this notice

to advise the public that an EIS will be

prepared for the construction of the

FDA Regional Office and Laboratory in

Jamaica, Queens County, New York.

FOR FURTHER INFORMATION CONTACT: Mr.

Peter A. Sneed, Asset Manager, U.S.

General Services Administration, Public

Buildings Service, 26 Federal Plaza,

Room 1609, New York City, NY 10278,

(212) 264–3581.

SUPPLEMENTARY INFORMATION: The GSA

will serve as lead agency and project

sponsor in the preparation and filing of

an EIS for the construction of the FDA

Regional Office and Laboratory in

Jamaica, Queens County, New York. The

proposed action would involve the

construction and operation of the

facility on an assemblage of two

properties located at the intersection

158th Street and Liberty Avenue.

Combined, these two properties are 4.25

acres (1.73 hectares) in size. The

existing FDA regional facilities are

located in Federal Building #2 of the

Federal Complex in Sunset Park,

Brooklyn, New York. Due to the

deteriorated condition of, and space

constraints in, the present facility, FDA

has requested relocation to a modern

expanded facility to accommodate the

additional staffing required to provide

increased oversight and product

monitoring. This action is intended to

provide 175,000 occupiable square feet

(16,250 square meters) of office, storage,

and special space.

The EIS will evaluate the FDA

regional facility alternatives, including

the No-Action Alternative. It will also

evaluate impacts on the affected

environment, including, but not limited

to, socioeconomics, hazardous

materials, traffic/transportation, land

use, cultural resources, and noise.
Federal Register / Vol. 60, No. 50 / Wednesday, March 15, 1995 / Notices 13999

PUBLIC SCOPING MEETING: To ensure that

all issues relating to the proposed

project are identified and all potentially

significant issues are addressed and

satisfied in the EIS, public comments

and suggestions are being solicited. To

facilitate the receipt of comments, a

public scoping meeting will be held on

Monday, March 20, 1995 from 2 p.m. to

4 p.m. and from 6 p.m. to 8 p.m. in the

auditorium of the Joseph Addabbo

Federal Building, 1 Jamaica Center

Plaza, Jamaica, New York.

Written comments may be mailed to

the informational contact person no

later than April 7, 1995.

Issued in New York City, New York on

March 7, 1995.

Karen R. Adler,

Regional Administrator, General Services

Administration, Region 2.

[FR Doc. 95–6289 Filed 3–14–95; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

Board of Scientific Counselors,

Agency for Toxic Substances and

Disease Registry: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Agency for Toxic

Substances and Disease Registry

(ATSDR) announces the following

committee meeting.

Name: Board of Scientific Counselors,

ATSDR.

Times and dates: 8:30 a.m.–5:00 p.m.,

April 20, 1995. 8:30 a.m.–12:40 p.m., April

21, 1995.

Place: The Centers for Disease Control and

Prevention, Auditorium A, 1600 Clifton

Road, NE, Atlanta, Georgia 30333.

Status: The entire meeting will be open to

the public.

Purpose: The Board of Scientific

Counselors, ATSDR, advises the

Administrator, ATSDR, on ATSDR programs

to ensure scientific quality, timeliness,

utility, and dissemination of results.

Specifically, the Board advises on the

adequacy of the science in ATSDR-supported

research, emerging problems that require

scientific investigation, accuracy and

currency of the science in ATSDR reports,

and program areas to emphasize and/or to deemphasize.

Agenda: The Agenda will include an

update on Superfund reauthorization and

will also focus on other issues of concern to

ATSDR, including ATSDR’s programs for

physician and community education,

development of the medical assistance

program, progress report by the Board of

Scientific Counselors, ATSDR, work group

on health studies, and an overview of the

ATSDR Great Lakes Human Health Effects

Research Program.

Written comments are welcome and should

be received by the contract person listed

below prior to the opening of the meeting.

Contact person for more information:

Charles Xintaras, Sc.D., Executive Secretary,

Board of Scientific Counselors, ATSDR,

Mailstop E–28, 1600 Clifton Road, NE.,

Atlanta, Georgia 30333, telephone 404/639–

0708.

Dated: March 8, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 95–6318 Filed 3–14–95; 8:45 am]

BILLING CODE 4163–70–M

National Institutes of Health Genome

Research Review Committee; Notice

of Cancellation of Meeting

Notice is hereby given of the

cancellation of the meeting of the

Genome Research Review Committee,

National Center for Human Genome

Research, March 14, 1995, Embassy

Suites Hotel, Chevy Chase Pavilion,

Washington, D.C. which was published

in the Federal Register on March 3, 1995

(60 FR 11975).

The meeting was cancelled due to

complications of other commitments of

several members of the committee and

will be rescheduled at a later date.

Dated: March 9, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6326 Filed 3–14–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meeting:

Name of SEP: Review of the Vascular

Disease Academic Award.

Date: April 9–10, 1995.

Time: 7 p.m.

Place: Holiday Inn, Chevy Chase,

Maryland.

Contact Person: S. Charles Selden, Ph.D.,

5333 Westbard Avenue, Room 552, Bethesda,

Maryland 20892, (301) 594–7476.

Purpose/Agenda: To review and evaluate

grant applications.

The meeting will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: March 9, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6398 Filed 3–14–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meeting:

Name of SEP: Mechanisms of Post Bone

Marrow Transplantation Lung Injury.

Date: April 5–6, 1995.

Time: 7:30 p.m.

Place: Holiday Inn, Chevy Chase,

Maryland.

Contact Person: Dr. Lynn M. Amende, 5333

Westbard Avenue, Room 5A10, Bethesda,

Maryland 20892, (301) 594–7480.

Purpose/Agenda: To review and evaluate

grant applications.

The meeting will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: March 9, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6397 Filed 3–14–95; 8:45 am]

BILLING CODE 4140–01–M